The BioPharm Brief: Breakthrough Signals in Cancer, Duchenne, and RNA Medicine

Welcome to The BioPharm Brief, your daily roundup of developments shaping the biopharmaceutical industry. Today’s episode focuses on encouraging clinical data in acute myeloid leukemia and Duchenne muscular dystrophy, along with a strategic licensing agreement aimed at strengthening cardiometabolic disease pipelines.

First, Aptevo Therapeutics reported strong new data from its frontline acute myeloid leukemia, or AML, RAINIER study. According to the company, its investigational therapy mipletamig, used in combination with venetoclax and azacitidine, demonstrated an 87% clinical benefit rate and an 81% remission rate across evaluable patients in the Phase 1b trial. The company says the study has now entered its final dose-optimization stage and remains on track for Phase 2 dose selection later this year. AML remains one of the more aggressive blood cancers, making remission durability and safety profiles key areas of focus for researchers and clinicians.

Meanwhile, Entrada Therapeutics announced positive topline results from its Phase 1/2 ELEVATE-44-201 study evaluating ENTR-601-44 in patients with Duchenne muscular dystrophy amenable to exon 44 skipping. The company reported statistically significant improvements in a functional movement assessment called Time to Rise velocity, along with favorable safety and tolerability findings. Researchers also observed increases in dystrophin production and exon skipping activity, two important biological markers tied to Duchenne treatment development.

And in pipeline news, GSK has expanded its cardiometabolic disease strategy through a licensing agreement for SiranBio’s siRNA candidate SA030. The deal reflects continued industry interest in RNA-based therapeutics and precision-targeted approaches for chronic metabolic conditions. GSK has increasingly emphasized pipeline growth in specialty and genetically informed disease areas.

Thanks for listening to The BioPharm Brief. For analysis and expert insights, please visit BioPharmInternational.com

KEY TAKEAWAYS

• Aptevo’s AML program reported high remission and clinical benefit rates as the RAINIER study advances toward Phase 2.
• Entrada Therapeutics showed early functional improvement and favorable safety data in Duchenne muscular dystrophy patients.
• GSK continues expanding its RNA-focused cardiometabolic pipeline through strategic licensing activity.